FDA Approves DORIBAX™ (doripenem for injection) for the Treatment of Complicated Intra-abdominal and Complicated Urinary Tract Infections

Story Summary:

The U.S. Food and Drug Administration (FDA) has approved DORIBAX™ (doripenem for injection) as a new treatment for complicated intra-abdominal and complicated urinary tract infections, including pyelonephritis. DORIBAX has demonstrated activity against a wide range of Gram-positive and Gram-negative bacteria – including Pseudomonas -- that cause these serious infections.

According to the CDC, in the U.S., nearly 2 million people acquire bacterial infections in hospitals each year, 90,000 will die as a result. 70% of those infections are caused by pathogens resistant to at least one drug. In 1998, the total annual cost of antimicrobial resistance to U.S. society was at least $5 billion USD. Gram-negative infections quickly are becoming a top concern of doctors in the hospital setting.

For more information visit: www.cdc.gov and www.who.int

Soundbites

• Joseph Solomkin, MD, Professor of Surgery and Director of Research, University of Cincinnati College of Medicine

B-Roll Includes

• Pathogen Images
• Patient and Hospital Footage
• Product and Manufacturing Footage

VIDEO PROVIDED BY: "Ortho-McNeil, Inc."